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Summary Genomic alterations have been analysed in 65 non-small-cell lung cancer (NSCLC) tissue samples by using the arbitrarily primed
polymerase chain reaction (AP-PCR), which is a PCR-based genomic fingerprinting. We have shown that AP-PCR may be applied as a useful
and feasible practical method for detection of the genomic alterations that accompany malignancy in NSCLC. Genomic changes detected by
us consisted of: allelic losses or gains in anonymous DNA sequences, homozygously deleted DNA sequences and polymorphic DNA
sequences. According to these genomic changes, lung tumours evaluated in the present study have been scored into three groups: low,
moderate and high genomic damage tumours. The aim of this study was to investigate the effect of genomic damage on patient survival.
Survival analysis was carried out in 51 NSCLC patients. Our results revealed that high genomic damage patients showed a poorer prognosis
than those with low or moderate genomic damage (P= 0.038). Multivariate Cox regression analysis showed that patients with higher genomic
alterations displayed an adjusted-by-stage risk ratio 4.26 times higher than the remaining patients (95% Cl = 1.03-17.54). We can conclude
that genomic damage has an independent prognostic value of poor clinical evolution in NSCLC.
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Cancer is the result of the accumulation of multiple genetic
changes in the tumour cell genome. Each alteration, whether an
initiating or a progression-associated event, may be mediated
through a gross chromosomal change and therefore has the
potential to be cytogenetically visible.
Several molecular genetic methods have been applied to detect
those genomic alterations in tumour DNAs. Arbitrarily primed
polymerase chain reaction (AP-PCR), a genomic fingerprinting
method (Welsh and McClelland, 1990; 1991), has become estab-
lished, in the last few years, as an efficient screening method to
detect novel genetic alterations in cancer cells (Peinado et al,
1992; Khono et al, 1994; Achille et al, 1996; Okazaki et al, 1996;
Vogt et al, 1996). The method relies on the selective amplification
of genomic sequences that, by chance, are flanked by adequate
matches to a primer whose nucleotide sequence is arbitrarily
chosen. Tumour-specific somatic genetic alterations can be readily
detected by comparison of the AP-PCR fingerprints from tumoral
and normal tissue ofthe same patient. Peinado et al (1992) applied
this fingerprinting method to analyse genetic alterations in
colorectal carcinomas and demonstrated that the decreased and
increased intensities of the PCR bands in tumour DNA represent
allelic losses and gains, respectively, of the corresponding
genomic fragments in cancer cells. Other investigators have iden-
tified a novel chromosomal locus homozygously deleted in a
human small-cell lung cancer (SCLC) cell line using AP-PCR
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genome fingerprinting (Kohno et al, 1994). In other studies, AP-
PCR has been applied for detection of amplified genomic
sequences in human SCLC cell lines (Okazaki et al, 1996).
In this investigation, we have undertaken a detailed AP-PCR
study to detect genomic alterations in non-small-cell lung carci-
nomas (NSCLCs). NSCLC originates mainly from bronchial
epithelial cells and represents the majority of human lung cancers.
These carcinomas are surgically managed if both the stage at
which diagnosis is made and the clinical status are appropriate.
Genomic DNA from 65 NSCLC patients undergoing radical
surgery was analysed by comparing DNA fingerprinting from
tumour tissues and their corresponding normal tissues. Changes
observed in tumour cells, including increases and decreases in the
relative intensity of the tumour band compared with the normal
control band, were considered.
The aims of this study were, first, to establish if AP-PCR tech-
nique could be important for analysis of the cancer genome and,
second, to investigate if a higher accumulation of genomic alter-
ations detected by this method, could be associated with a poor
clinical evolution in NSCLC patients. In addition, we tried to
establish a relationship between AP-PCR genomic alterations and
other molecular changes considered to be most prevalent in lung
tumours, such as K-ras and p53 mutations (Slebos et al, 1990;
Rodenhuis and Slebos, 1992; Horio et al, 1993; Mitsudomi et al,
1993; Vega et al, 1996; 1997), as well as c-myc overexpression,
considered as a relatively late event in the lung cancer develop-
ment (Bergh, 1990). Our results suggest that AP-PCR may be
applied as a useful and feasible practical screening method for
detection of novel somatic genomic alterations in NSCLC and
could be used with a diagnostic and/or prognostic purpose.
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MATERIALS AND METHODS
Patients and tumour samples
Non-small-cell lung carcinomas and corresponding normal tissues
were obtained from 65 patients (64 men and 1 woman) with a
median age of 62.2 ± 9.25 years, who underwent surgery between
1992 and 1994 at the San Carlos Hospital (Madrid, Spain). No
specific decision was taken to restrict this study to male patients;
patients were included in a consecutive way. During surgery, two
tissue samples were obtained: from the tumoral specimen and
from normal lung parenchyma (at least 4 inches away from the
distal margin of the neoplasm). All tissue samples were snap-
frozen in liquid nitrogen immediately after surgery and stored
at -80°C. Cryostat-sectioned, haematoxylin and eosin-stained
samples from each tumour block were examined microscopically
by two independent pathologists to confirm the presence of > 80%
tumour cells. Paired normal tissues from the same individual were
used as control.
Histological classification of the tumours was based on the
WHO classification (WHO, 1981). The distribution of the histo-
logical types was 40 (61.5%) squamous cell carcinomas (SCC), 16
(24.6%) adenocarcinomas (AC) and nine (13.8%) large cell undif-
ferentiated carcinomas (LCUC). According to differentiation
grade, eight (12.3%) tumours were scored as well differentiated,
31 (47.7%) moderately and 26 (40%) poorly differentiated.
Tumours were pathologically staged using the tumour node metas-
tasis (TNM) system (Mountain, 1986) and consisted of 30 (46. 1%)
stage I tumours, five (7.7%) stage II, 23 (35.4%) stage IIIA) three
(4.6%) stage IIIB and four (6.2%) stage IV.
Patients who had stage I, II and IIIA tumours were subjected to
curative surgery, whereas only a biopsy was taken from patients
who suffered greater disease extension (tumours in stages IIIB and
IV). Patients with resected tumour were seen at 3-month intervals
during the first 3 years of follow-up in order to perform clinical
examination, chest radiography and serum tumour marker
analysis. Bronchoscopy, and thorax and upper abdominal (CT)
computerized tomography were performed twice a year. During
the next 2 years, visits and exploration were reduced to half.
DNA isolation
Genomic DNA from all samples was prepared by proteinase K and
the phenol-chloroform extraction method as described previously
(Blin and Stafford, 1976).
AP-PCR
AP-PCR is a PCR-based method for DNA fingerprinting (Welsh
and McClelland, 1990; 1991). Amplifications, using a single arbi-
trary primer, were performed under low-stringency conditions in
the initial cycles in order to hybridize the arbitrary primers to
many sequences in the total genomic DNA. Then, following
cycles under high-stringency conditions allow only the best
matches ofthe initial events to be amplified further.
Genomic DNA (25-50 ng) was incubated with 0.75 units of Taq
DNA polymerase (Perkin Elmer, Roche, NJ, USA) and 1 unit of
Taq DNA polymerase Stoffel fragment (Perkin-Elmer, Roche, NJ,
USA), 200 gM of each dNTP (Pharmacia, Biotech, Uppsala,
Sweden), 1-2 tCi of [a_32p] dCTP (3000 Ci mmol-', Amersham,
UK), 10 mM Tris-HCl (pH 8.3), 50 gM potassium chloride, 2.5 mM
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Figure 1 AP-PCR analysis of non-small-cell lung tumours. Autoradiograms
of 32P-labelled DNA fragments amplified by AP-PCR are shown. Total
genomic DNA (50 ng) from normal (N) and tumoral (T) tissue pairs of the
patients indicated at the top was amplified with primers 6i (A) and 5-6a (B).
Increases and decreases in the intensity of tumour bands are indicated with
arrowheads and denominations as used in the text
magnesium chloride and 0.5 gM ofan arbitrary primer, in a volume
of 25 gl. Primer sequences were as follows: 5-6a: 5'-AGTTG-
CAAACCAGACCTCAG-3'; 6s: 5'-CACTGATTGCTCTTAGGT-
CTG-3'; 6i: 5'-TCTTAGGTCTGGCCCCTCCT-3'.
Primer selection was completely arbitrary, this means that there
was no intentional bias in favour or against any type of sequence.
We evaluated single primers that had been previously used in our
laboratory for other studies. Those primers generating an adequate
amplification pattern from genomic DNA were chosen for the AP-
PCR experiments.
Amplification reactions were carried out in a 2400 GeneAmp
PCR system (Perkin-Elmer) for five cycles under low-stringency
conditions (95°C for 45 s, 40°C for 30 s and 72°C for 1.15 min)
followed by 35 cycles under higher stringency conditions (95°C
for 45 s, 60°C for 30 s and 72°C for 1 min). Denatured PCR prod-
ucts were analysed in 6% denaturing polyacrylamide/7 M urea gels
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Figure 2 AP-PCR DNA fingerprinting of normal (N) and tumoral (T) tissue
pairs of the patients indicated at the top, amplified with primer 6s.
Polymorphic DNA sequences are indicated on the left with arrowheads and
with denominations as used in the text. Sizes of bands, in nucleotides (nt),
are indicated on the right. Note that patient 75 is shown in duplicate.
Reproducible fingerprints were obtained in both cases
at 7 W for 18 h at room temperature. The gels were dried and
exposed to radiograph film.
Quantification of DNA fingerprinting tumour bands
By using AP-PCR, we generated complex DNA fingerprints
consisting of 40-50 bands for each patient and for a given primer
used. Because of the great number of bands to be analysed by
comparing intensity changes between normal and tumour bands,
we first selected all the changes detected by two independent
observers. After this previous screening, we confirmed and quanti-
fied the rates of changes by using a Biolmage IQ and TDI IQ+
software (TDI, Spain) for gel electrophoresis. Intra- and interassay
reproducibility was assessed. For intra-assay variability, DNA
samples were analysed in duplicate, i.e. patient 75 in Figure 2.
Results revealed that reproducible DNA fingerprints were
obtained in both cases. For interassay reproducibility, ten normal-
tumour tissue pairs, randomly selected from the sample collection,
were analysed with primers 5-6a and 6s three to five times.
Reproducibility analysis indicated that band intensity changes of
up to 20% could be produced by interassay variability. In conse-
quence, increased and decreased intensities of tumour bands were
only considered when amplification or reduction in signal intensity
from tumour tissue, in comparison to the corresponding signal
from the normal control tissue, was greater than 20%. Only cases
displaying a similar level of amplification (lane overall intensity)
of the normal and tumour fingerprints were considered for
analysis. Unequal amplification ofboth lanes could be due to poor
DNA quality or reaction failure. Of all the normal-tumour tissue
DNA fingerprinting pairs analysed in this study (65 x 3 = 195),
only ten (5%) displayed non-reproducible fluctuations in the in
vitro amplification. In these cases quantitative changes could be
spurious and were not considered for AP-PCR analysis.
Detection of K-ras, c-myc and p53 genetic alterations
The detection of K-ras point mutations was performed as
described by Vega et al (1996). p53 gene mutations were detected
as describedby Vega et al (1997). Accumulation ofthe p53 protein
in the tumour cell nuclei was detected as described by Vega et al
(1997). C-myc overexpression was evaluated by Northern blot
analysis (unpublished results).
Statistical analysis
Molecular abnormalities previously investigated in the tumour
population analysed in this study, such as K-ras mutations, p53
alterations and c-myc overexpression, were correlated with data
obtained from AP-PCR analysis. Clinicopathological characteris-
tics of tumours analysed were also correlated with results from
AP-PCR. Results were evaluated by the chi-square test and a
P- value < 0.05 wasjudged to be statistically significant.
Survival analysis was carried out with patients whose clinical
evolution was followed up for at least 24 months. We only consid-
ered patients with I, II and IIIA tumours, and patients who had died
in the post-operative period were also excluded. Thus, the number
ofpatients included in the survival study was 51.
Survival curves were calculated using the Kaplan-Meier
method and compared using the log-rank test. Results were
considered significant for P-values < 0.05. The Cox proportional
hazards model for univariate analysis was applied to calculate risk
ratios and 95% confidence intervals. Multivariate analysis using
the proportional hazards model ofCox was used to estimate simul-
taneously the relative strength ofmultiple covariates to assess their
statistical independence.
RESULTS
AP-PCR DNA fingerprinting of non-small-cell lung
carcinomas
It was possible to generate reproducible fingerprints of normal-
tumour tissue DNA pairs from 65 patients with NSCLC using AP-
PCR. Figures 1 and 2 show representative experiments, each
obtained using a different arbitrary primer: 6i (Figure IA), 5-6a
(Figure 1B) and 6s (Figure 2), (for sequences see Materials and
methods). We analysed 130 samples of genomic DNA (65 normal
control and 65 tumour samples). Each normal-tumour tissue pair
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Table 1 Relationship between molecular abnormalities and genomic alterations detected using AP-PCR
K-ras gene c-myc mRNA p53 protein p53 gene
Genomic Number mutations overexpression accumulation mutations
damage of cases number (%) number (%) number (%) number (%)
Low 23 5 (21.7) 5 (21.7) 12 (52) 4 (17.4)
Moderate 30 8 (26.7) 11 (36.6) 17 (56.7) 7 (23.3)
High 12 0 (0) 5 (41.7) 8 (66.7) 4 (33.3)
Total 65 13 (20) 21 (32) 37 (56.9) 15 (23)
P-value 0.143 0.383 0.712 0.568
was analysed with the arbitrary primers mentioned above. Thus, a
total of 390 DNA fingerprints were analysed in this study. For a
given primer, band patterns consisted of40-50 DNA fragments of
sizes ranging from 200 to 1000 nt. The average number of DNA
bands obtained with the three arbitrary primers used was
138.8 ± 3.3. When we analysed the AP-PCR fingerprints we
detected changes in the intensity of several bands. Increased or
decreased intensities in tumour bands relative to their corre-
sponding normal bands were observed. For instance, the density of
bands Dl and D2 oftumour 50 (Figure 1A) was reduced compared
with its normal tissue band. The same tumour also showed some
higher molecular weight DNA fragments with a greater density
than the normal bands (1, 2 and 3). Other examples of tumour
increased bands were bands 14, 15 and 16 of tumour 39 (Figure
1B). This tumour also showed a decreased intensity band in rela-
tion to its normal control band (D3). Band P3 of tumour 77 was
another apparent case of decreased intensity band (Figure 2). The
frequency of the increased intensity tumour bands (gains) was
higher than the decreased ones (losses). Sixty-four per cent of all
genomic changes analysed by us consisted of gains in the corre-
sponding genomic fragments.
In addition, in some cases we detected changes when comparing
DNA fingerprints obtained from different patients. These differ-
ences represented polymorphism in the human population because
they were present in both normal and tumour tissues from many
patients. For instance, band P1 was absent in patients 63, 75 and
16 (Figure 2) and band P2 was also absent in patients 13 and 75
(Figure 2). At the bottom of Figure 2 there was a case of length
polymorphism (bands P3 upper and lower). There were some
patients with an upper P3 band (87 and 73), patients with a lower
P3 band (75, 16 and 77) and other patients showed both of them
(11, 13, 63, 69 and 71). These bands appeared to represent two
alleles from the same polymorphic locus.
Finally, P3 bands present in normal tissue were apparently
absent in tumoral tissue from patients 11 and 71, suggesting that
these sequences were homozygously deleted in both of them
(Figure 2).
Quantification of genomic damage
Changes observed in tumoral tissue related to normal tissue were
analysed, taking into account increases and decreases in the rela-
tive intensity of the tumour bands. For a given patient, the total
number of changes detected by AP-PCR was divided by the total
number of bands obtained with the three arbitrary primers used in
this study (138.8 ± 3.3). For instance, in tumour 50 five changes
were detected with primer 6i (three increases and two decreases)
(Figure IA); eight changes with primer 6s (five increases and three
decreases); and four changes with primer 5-6a (three increases
and one decrease). Thus, the total number ofchanges detected was
17 and the total number ofbands obtained with primers 6i, 6s and
5-6a was 142. The quotient obtained from these two values was
taken as the degree of AP-PCR genomic damage for this patient.
According to the distribution ofthe degrees ofgenomic damage in
NSCLC patients, tumours evaluated in the present study were
subjectively classified into three groups: low, moderate and high
genomic damage tumours. Twenty-three patients (35%) had low
damage, 30 (46%) had moderate damage and 12 (18%) had high
genomic damage. The first group of tumours showed a number of
genomic changes of 5.1 ± 2.5. The degree ofgenomic damage for
these tumours was < 0.07. Moderate genomic damage tumours
displayed a number of alterations of 12.6 ± 2.6. In this case the
degree of genomic damage ranged between 0.07 and 0.140.
Finally, high genomic damage tumours showed an average number
of 20.1 ± 3.5 changes and a degree ofgenomic damage > 0.140.
No significant correlation was found between genomic damage
and the clinicopathological characteristics of the tumours
analysed, such as tumour stage, histological type and differentia-
tion grade.
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Figure 3 Survival curves using Kaplan-Meier analysis of radically resected
NSCLC patients in relation to genomic damage (only patients who had stage
1,11 and IIIA tumours and excluding patients who had died in the post-
operative period). The median follow-up period was 110 weeks. High
genomic damage patients (-) vs low and moderate genomic damage
patients (--), P= 0.038 using the log-rank test
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Table 2 Results of univariate risk estimates for survival according to Cox proportional hazards model for prognostic variables in stages 1, 11 and IIIA tumours of
NSCLC patients (n = 51)
Factor Category Risk ratio 95% Cl P
Genomic damage (AP-PCR) High vs low + moderate 2.71 0.89-8.23 0.10
Stage II vs 6.50 1.07-39.26
IIIAVs 6.87 1.48-31.93 0.01
Histology Squamous cell vs
adenocarcinoma 1.34 0.29-6.24 0.70
Differentiation grade Poor vs well + moderate 1.37 0.47-3.97 0.55
Cl = confidence interval.
Table 3 Results of multivariate risk estimates for survival according to Cox proportional hazards model for prognostic variables in stages 1, 11 and "'A tumours
of NSCLC patients (n = 51)
Factor Category Risk ratio 95% Cl P
Genomic damage (AP-PCR) High vs low + moderate 4.26 1.03-17.54 0.04
Stage II vs 3.00 0.43-20.74 0.27
IIIAVs 8.66 1.79-41.77 0.01
Cl = confidence interval.
Genomic alterations detected by AP-PCR in relation to
other molecular abnormalities
Previous studies carried out in our laboratory investigated K-ra.s-
activating point mutations in a group ofNSCLC patients, including
all the patients considered in this study. Furthermore, we investi-
gated p53 protein accumulation and p53 gene mutations in all these
tumours, as well as c-myc overexpression. Taking into account
these studies, we have investigated if there was a relationship
between the molecular changes mentioned above and the genomic
alterations detected by AP-PCR. The results obtained did not show
a significant association between these parameters (Table 1).
Effect of AP-PCR genomic alterations on patient
survival
After molecular genomic analysis, a statistical analysis was
performed to examine the prognostic significance of genomic
alterations detected by AP-PCR in NSCLC patients.
Kaplan-Meier survival curves have shown that patients with
high genomic damage have a worse prognosis than those with a
low or a moderate level ofgenomic alterations (P = 0.038) (Figure
3). When a univariate Cox regression analysis was performed, the
variable stage was the only significant prognostic factor (P = 0.01)
(Table 2). Patients who had stage II and IIIA tumours showed a risk
ratio much higher than those who had stage I tumours. The vari-
able genomic damage (AP-PCR) did not reach statistical signifi-
cance (P = 0.10), but the risk ratio of patients with high vs
low + moderate genomic damage was 2.71 (95% CI = 0.89-8.23).
To assess the independence of genomic damage and stage as
possible prognostic indicators, multivariate Cox regression analysis
was performed. As noted in Table 3, patients with high genomic
damage showed an adjusted-by-stage risk ratio 4.26 times higher
than the remaining patients (95% CI = 1.03-17.54). When stage
IIIA tumour patients were compared with those in stage I, an
adjusted risk ratio of 8.66 (95% CI = 1.79-41.77) was calculated.
DISCUSSION
In this study, genomic alterations occurring in NSCLC have been
analysed using AP-PCR. Genomic damage detected by this tech-
nique has been associated with clinical evolution ofNSCLC patients.
AP-PCR offers immediate application as an alternative approach to
examine genomic damage in cancer cells. In the last few years, this
DNA fingerprinting method has been successfully applied to the
investigation of genomic alterations in colorectal tumours (Peinado
et al, 1992), human small-cell lung cancer (SCLC) cell lines (Khono
et al, 1994; Okazaki et al, 1996), pancreatic carcinoma (Achille et al,
1996) and skin tumours (Vogt et al, 1996).
In this study, we have shown that AP-PCR is very useful for the
detection and the characterization of genomic alterations that
accompany malignancy in NSCLC. These abnormalities consisted
of: (a) increases or decreases in the intensity of tumour bands rela-
tive to normal bands from the same individual; (b) differences
because of polymorphism in the human population; and (c)
homozygously deleted sequences in some tumour tissues.
(a) Regarding intensity differences in arbitrarily primed PCR
tumour bands, previous studies reported by Peinado et al
(1992) demonstrated that decreased and increased intensities
of the AP-PCR bands in tumour DNA represent allelic losses
and gains, respectively, of the corresponding genome frag-
ments in cancer cells. Allelic losses could be due to their
linkage to suppressor genes and gains might reflect the pres-
ence of extra copies of those sequences, which could be due to
gene amplification or to chromosomal imbalance as a result of
the tumour cell aneuploidy. The possibility of detecting
moderate gains of genetic material, such as those corre-
sponding to triploidy and tetraploidy, represents a significant
technical development because such genomic changes cannot
be readily detected through conventional allelotyping by
restriction fragment length polymorphism or by typing of
microsatellites.
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We have shown that gains in genomic sequences occur at high
frequency (64% of all genomic changes analysed) in non-
small-cell lung carcinomas. A frequent presence ofamplifica-
tions ofmultiple loci in cancer cell lines and primary tumours
has been demonstrated by molecular cytogenetic analysis
(Kallioniemi et al, 1992, 1993; Ried et al, 1994). The high
proportion ofgains in genomic sequences in our lung tumour
samples may indicate a main role of moderate increases in
gene copy number in NSCLC.
(b) In addition, we have detected another type ofchange present
only in a few ofthe patients considered in this study, in both
normal and tumour tissues. These differences represent poly-
morphisms in the human population. DNA polymorphism
analysis by AP-PCR has been widely used to identify bacterial
species and strains as well as plant varieties (Gomez-Lus et al,
1993; Martinez-Murcia et al, 1994; Perolat et al, 1994; Yi et
al, 1995).
(c) Finally, we have found homozygously deleted sequences in
some tumour tissues. Chromosomal deletions in human
tumours have been regarded as evidence that the affected
regions contain tumour-suppressor genes (Weinberg, 1991).
Several ofthese genes have been cloned from the regions of
homozygous deletions in human cancer (Friend et al, 1986).
Previous studies of Khono et al (1994) reported that a
homozygous deletion was detected by AP-PCR genomic
fingerprinting at chromosome 2q33 in a human SCLC cell
line, suggesting the presence of a novel tumour-suppressor
gene. These results demonstrated the use ofthe AP-PCR tech-
nique for the detection and characterization of genes that may
be involved in lung carcinogenesis.
Considering all the genomic alterations detected in the non-
small-cell lung tumours analysed in this study, we have classified
them into three different groups according to the higher or lower
incidence of these molecular changes. Once these groups of
tumours were established, we tried to correlate the incidence of
genomic damage detected by AP-PCR with clinicopathological
features of tumours, as well as with some prevalent genetic abnor-
malities previously investigated by us in these lung tumours, such
as K-ras mutations (Vega et al, 1996), p53 alterations (Vega et al,
1997) and c-mvc overexpression (unpublished results). When we
correlated the incidence of genomic damage with tumour stage,
histology and differentiation, our results did not show significant
differences. Besides, when we investigated if the incidence of
genomic damage had any relationship with the genetic abnormali-
ties mentioned above, our results showed that there was a non-
significant association between these parameters. Other significant
genetic changes in lung cancer such as 3p deletions, microsatellite
instability and changes in telomerase activity should be investigated
in relation to genomic damage. At the moment we are performing
studies conducted to investigate the relationship between genomic
alterations and microsatellite instability. Data obtained from this
study would also be useful to recognize if defects in DNA repair
pathways constitute a route for human carcinogenesis that predis-
pose to an increase in mutations in the genome.
We have considered an obvious direct application of the AP-
PCR technique for cancer prognosis. The association between
genomic aberrations detected using this method and patient
survival, to our knowledge, has not been described previously in
NSCLC. Our results showed a significant poorer prognosis in
NSCLC patients with a higher prevalence of genomic alterations.
Multivariate Cox regression analysis also showed that tumour
genomic alterations and tumour stage could be considered as inde-
pendent prognostic markers. Taking together all these results, it
seems that there is enough evidence to suggest that a high level of
genomic alterations may have a predictive prognostic value in
NSCLC patients.
In conclusion, our results indicate, first, that AP-PCR is a
feasible and useful technique for detection and characterization of
novel genomic alterations in NSCLC, and, second, that genomic
damage has an independent prognostic value of poor clinical
evolution in NSCLC.
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